Immune cell helps prevent kidney cancer recurrence

Recurrence occurs when cancer comes back after surgery, or after a period of time being cancer-free. For people with clear cell renal cell carcinoma (RCC), the most common type of kidney cancer, the recurrent cancer can spread and develop into metastatic disease, despite treatment. A new study from researchers at Columbia University in the USA […]

read more

Local and regional recurrences of localised kidney cancer after nephrectomy

In this study 15 years of data from a single hospital were assessed to look at the outcomes of people who had had surgery for localised renal cell carcinoma (RCC). Of the 1895 people who were assessed, 30 (1.6%) had a single local recurrence of their cancer without distant spread (metastases). In total, 26 of […]

read more

Potential biomarker to predict risk of recurrence after nephrectomy for locally advanced kidney cancer

Currently, the search for a reliable biomarker to identify those patients who are at risk of the cancer coming back after nephrectomy for renal cell carcinoma (RCC) has not been successful. A recent study looked at a protein called kidney injury molecule-1 (KIM-1) in patients with RCC and whether this protein could be used to […]

read more

Predictive factors for recurrence after complete metastasectomy in metastatic kidney cancer patients

In this retrospective study, published in Science Direct this month, researchers were looking to identify the factors that would help to predict whether the cancer would come back after surgical removal of renal cell carcinoma (RCC) metastases (metastasectomy). Complete metastasectomy is expected to improve the survival of patients with metastatic RCC. However, for many patients […]

read more

Long-term risk of recurrence after surgery for kidney cancer

A recent study published in the journal European Urology investigated the long-term risk of recurrence in people who had had a nephrectomy for the treatment of localised renal cell carcinoma (RCC) in order to determine the usefulness of long-term follow-up (surveillance). A retrospective analysis of 1943 patients who took part in the ECOG E2805 clinical […]

read more

Incidence and pattern of recurrence of kidney cancer after robotic partial nephrectomy

A recent study has shown the incidence and pattern of recurrence of renal cell carcinoma (RCC) in patients who underwent robotic partial nephrectomy for a small renal mass between September 2009 and March 2018. A total of 335 patients with a small renal mass underwent robotic partial nephrectomy, 269 patients of which were found to […]

read more

Sorafenib versus observation following surgery for metastatic kidney cancer

A potential treatment for a selected group of patients with metastatic renal cell carcinoma (RCC) is nephrectomy followed by surgery to remove metastases (radical metastasectomy). After surgery, patients are usually followed by observation or treated with anti-cancer drugs. The RESORT clinical trial assessed the potential benefit of treatment with sorafenib after radical metastasectomy compared with […]

read more

Potential kidney cancer test in development

A Swedish biotechnology company, Elypta, has recently been awarded an EU grant for the development of a new test for the diagnosis of renal cell carcinoma (RCC). The grant of ¬£2.4m will be used to run a clinical trial to validate Elypta’s technology as a tool for monitoring patients who have been treated for RCC […]

read more

High levels of distress among people with kidney cancer

A recent study published in BJU International¬†reports high levels of distress among people with the most common form of kidney cancer, renal cell carcinoma (RCC). Four hundred and fifty (450) people were surveyed online from April to June 2017. Most patients where white (93 %) and more than half were women (56 %). The mean […]

read more

ESMO 2018: Adjuvant axitinib versus placebo in patients at high risk of RCC recurrance

Results from the latest adjuvant study with a vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI), axitinib (Inlyta), were presented at the European Society of Medical Oncology (ESMO) 2018 conference in Munich over the weekend. Results of clinical trials assessing adjuvant therapy for intermediate- and high-risk renal cell carcinoma (RCC) with VEGF TKIs have […]

read more
Showing 1 to 10 of 15 results
  TOP